Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial
Top Cited Papers
Open Access
- 5 December 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 57 (3), 1153-1162
- https://doi.org/10.1002/hep.26185
Abstract
Acute‐on‐chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin dialysis with the molecular adsorbent recirculating system (MARS) decreases retained substances and improves hemodynamics and hepatic encephalopathy (HE). However, its survival impact is unknown. In all, 189 patients with ACLF were randomized either to MARS (n = 95) or to standard therapy (SMT) (n = 94). Ten patients (five per group) were excluded due to protocol violations. In addition, 23 patients (MARS: 19; SMT: 4) were excluded from per‐protocol (PP) analysis (PP population n = 156). Up to 10 6‐8‐hour MARS sessions were scheduled. The main endpoint was 28‐day ITT and PP survival. There were no significant differences at inclusion, although the proportion of patients with Model for Endstage Liver Disease (MELD) score over 20 points and with spontaneous bacterial peritonitis (SBP) as a precipitating event was almost significantly greater in the MARS group. The 28‐day survival was similar in the two groups in the ITT and PP populations (60.7% versus 58.9%; 60% versus 59.2% respectively). After adjusting for confounders, a significant beneficial effect of MARS on survival was not observed (odds ratio [OR]: 0.87, 95% confidence interval [CI] 0.44‐1.72). MELD score and HE at admission and the increase in serum bilirubin at day 4 were independent predictors of death. At day 4, a greater decrease in serum creatinine (P = 0.02) and bilirubin (P = 0.001) and a more frequent improvement in HE (from grade II‐IV to grade 0‐I; 62.5% versus 38.2%; P = 0.07) was observed in the MARS group. Severe adverse events were similar. Conclusion: At scheduled doses, a beneficial effect on survival of MARS therapy in patients with ACLF could not be demonstrated. However, MARS has an acceptable safety profile, has significant dialysis effect, and nonsignificantly improves severe HE. (HEPATOLOGY 2013)Keywords
This publication has 31 references indexed in Scilit:
- Risk factors for long-term mortality in a large cohort of patients wait-listed for liver transplantation in BrazilLiver Transplantation, 2011
- Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulationCritical Care, 2011
- Early features of acute-on-chronic alcoholic liver failure: a prospective cohort studyGut, 2010
- Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failureCritical Care, 2009
- Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosisHepatology, 2007
- Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failureCritical Care, 2006
- Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitisJournal of Hepatology, 2005
- Acute liver failure: current management and future prospectsJournal of Hepatology, 2004
- Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failureLiver International, 2003
- Acute-on-Chronic Liver Failure: Pathophysiological Basis of Therapeutic OptionsBlood Purification, 2002